Spasm Artery Clinical Trial
Official title:
Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary Intervention
| Verified date | February 2022 |
| Source | University of Monastir |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Radial artery is the recommended route for percutaneous coronary intervention for it significantly reduces net adverse clinical events compared to the femoral approach. The success of the radial approach is therefore of a paramount importance. However, radial artery spasm (RAS) remains one of the major limitations of transradial approach (TRA) and the most frequent cause of TRA failure. Several recommendations has been issued to improve success rate when using the radial route. In the Tunisian difficult economic context, the use of low end equipment, the unavailability of nitroglycerine and calcium antagonist verapamil, has led to the general feeling that RAS and TRA failure has subsequently increased. The standard and only used protocol by the Tunisian interventional cardiologist, consists of administrating 1 mg isosorbide dinitrate through the arterial sheath immediately after radial arterial puncture, therefore limiting the options to prevent RAS. Nicardipine is the only injectable calcium antagonist available in Tunisia. Its spasmolytic action on radial artery has been well demonstrated when used in CABG. However, it has been very poorly investigated in trans radial percutaneous coronary intervention. Investigators believe that the concomitant use of nicardipine with isorbide might significantly reduce RAS and TRA failure when compared to isosorbide dinitrate only.
| Status | Completed |
| Enrollment | 1500 |
| Est. completion date | February 1, 2022 |
| Est. primary completion date | February 1, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - All patients scheduled for coronary intervention will be eligible for screening (coronarography or coronary angioplasty). - Participant is willing and is able to give informed consent for participating in the trial. - Male or Female, aged 18 years or above. Exclusion Criteria: - Planned femoral approach because no radial pulse was perceived - Cardiogenic shock - Coronary intervention for ST elevation myocardial infarction during the night shift. |
| Country | Name | City | State |
|---|---|---|---|
| Tunisia | CHU Fattouma Bourguiba | Monastir |
| Lead Sponsor | Collaborator |
|---|---|
| Pr. Semir Nouira |
Tunisia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants in which radial artery spasm occurred | Significant limitation of the catheter movement perceived by the operator together with mild to severe pain in the forearm of the patient or the need of repeating vasodilator administration | 24 hours | |
| Secondary | Number of Participants in which severe radial artery spasm occurred | Complete catheter blockage [i.e., the catheter cannot be moved back or forth], severe pain with need for morphine or midazolam injections, crossover to the contralateral radial or femoral artery | 24 hours |